Market Place
Sourcing Support
Memgen Announces Data on MEM-288 in Advanced/Metastatic NSCLC
06 Jun 2023 //
BUSINESSWIRE
Memgen Reports Results From Its First-In-Human Trial of MEM-288 in Solid Tumors
30 Nov 2022 //
BUSINESSWIRE
Memgen Appoints Kevin M. Coveney as Chief Financial Officer
17 Nov 2021 //
BUSINESSWIRE
Memgen Announces Research to Be Presented at 2020 (AACR) Meeting
02 Jun 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.